JP2006528627A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2006528627A5 JP2006528627A5 JP2006520939A JP2006520939A JP2006528627A5 JP 2006528627 A5 JP2006528627 A5 JP 2006528627A5 JP 2006520939 A JP2006520939 A JP 2006520939A JP 2006520939 A JP2006520939 A JP 2006520939A JP 2006528627 A5 JP2006528627 A5 JP 2006528627A5
- Authority
- JP
- Japan
- Prior art keywords
- natural killer
- killer cells
- alloreactive
- therapeutic antibody
- use according
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 210000000822 natural killer cell Anatomy 0.000 claims 34
- 230000001225 therapeutic effect Effects 0.000 claims 23
- 239000000203 mixture Substances 0.000 claims 8
- 239000012634 fragment Substances 0.000 claims 6
- 101000917858 Homo sapiens Low affinity immunoglobulin gamma Fc region receptor III-A Proteins 0.000 claims 4
- 101000917839 Homo sapiens Low affinity immunoglobulin gamma Fc region receptor III-B Proteins 0.000 claims 4
- 102100029185 Low affinity immunoglobulin gamma Fc region receptor III-B Human genes 0.000 claims 4
- 239000003814 drug Substances 0.000 claims 3
- 229960004641 rituximab Drugs 0.000 claims 3
- 230000010056 antibody-dependent cellular cytotoxicity Effects 0.000 claims 2
- 201000010099 disease Diseases 0.000 claims 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 2
- 229940079593 drug Drugs 0.000 claims 2
- 208000035473 Communicable disease Diseases 0.000 claims 1
- 206010028980 Neoplasm Diseases 0.000 claims 1
- 201000011510 cancer Diseases 0.000 claims 1
- 208000026278 immune system disease Diseases 0.000 claims 1
- 208000015181 infectious disease Diseases 0.000 claims 1
- 230000002458 infectious effect Effects 0.000 claims 1
- 239000008194 pharmaceutical composition Substances 0.000 claims 1
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US48950903P | 2003-07-24 | 2003-07-24 | |
| PCT/IB2004/002637 WO2005009466A1 (en) | 2003-07-24 | 2004-07-23 | Methods and compositions for increasing the efficiency of therapeutic antibodies using alloreactive natural killer cells |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2006528627A JP2006528627A (ja) | 2006-12-21 |
| JP2006528627A5 true JP2006528627A5 (enExample) | 2007-07-26 |
Family
ID=34102891
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2006520939A Pending JP2006528627A (ja) | 2003-07-24 | 2004-07-23 | アロ反応性ナチュラルキラー細胞を使用する治療用抗体の有効性を増加するための方法および組成物 |
Country Status (4)
| Country | Link |
|---|---|
| US (1) | US20060240005A1 (enExample) |
| EP (1) | EP1648508A1 (enExample) |
| JP (1) | JP2006528627A (enExample) |
| WO (1) | WO2005009466A1 (enExample) |
Families Citing this family (18)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2008019379A2 (en) * | 2006-08-07 | 2008-02-14 | Pdl Biopharma, Inc. | Use of allogeneic effector cells and anti-cs1 antibodies for selective killing of multiple myeloma cells |
| GB0707208D0 (en) * | 2007-04-13 | 2007-05-23 | Istituto Superiore Di Sanito | Novel disease treatments |
| EP2111869A1 (en) | 2008-04-23 | 2009-10-28 | Stichting Sanquin Bloedvoorziening | Compositions and methods to enhance the immune system |
| EP2493486A1 (en) * | 2009-10-30 | 2012-09-05 | University Of Arkansas For Medical Science | Use of autologous effector cells and antibodies for treatment of multiple myeloma |
| US11219672B2 (en) | 2014-08-07 | 2022-01-11 | Haruki Okamura | Therapeutic agent for cancer which comprises combination of IL-18 and molecule-targeting antibody |
| US10617757B2 (en) | 2014-08-08 | 2020-04-14 | The Regents Of The University Of California | Methods for treating multiple myeloma |
| WO2017042393A1 (en) * | 2015-09-11 | 2017-03-16 | Emercell Sas | Pooled nk cells from umbilical cord blood associated with antibodies and their uses for the treatment of disease |
| WO2018083080A2 (en) | 2016-11-04 | 2018-05-11 | Innate Pharma | Nkp46 ligand |
| AU2018265534A1 (en) * | 2017-05-11 | 2019-10-31 | Nantkwest, Inc. | Anti-EGFR/high affinity NK-cells compositions and methods for chordoma treatment |
| JP6647240B2 (ja) | 2017-05-12 | 2020-02-14 | 米満 吉和 | 高活性ｎｋ細胞、およびその利用 |
| WO2019154509A1 (en) | 2018-02-09 | 2019-08-15 | Pupil Labs Gmbh | Devices, systems and methods for predicting gaze-related parameters |
| EP3749172B2 (en) | 2018-02-09 | 2025-01-01 | Pupil Labs GmbH | Devices, systems and methods for predicting gaze-related parameters |
| WO2019154511A1 (en) | 2018-02-09 | 2019-08-15 | Pupil Labs Gmbh | Devices, systems and methods for predicting gaze-related parameters using a neural network |
| US11537202B2 (en) | 2019-01-16 | 2022-12-27 | Pupil Labs Gmbh | Methods for generating calibration data for head-wearable devices and eye tracking system |
| JP6697611B2 (ja) * | 2019-05-20 | 2020-05-20 | 吉和 米満 | 高活性ｎｋ細胞、およびその利用 |
| EP3979896B1 (en) | 2019-06-05 | 2024-11-13 | Pupil Labs GmbH | Devices, systems and methods for predicting gaze-related parameters |
| EP3987380B1 (en) | 2019-06-18 | 2024-10-16 | Pupil Labs GmbH | Systems and methods for determining one or more parameters of a user's eye |
| US12140771B2 (en) | 2020-02-19 | 2024-11-12 | Pupil Labs Gmbh | Eye tracking module and head-wearable device |
Family Cites Families (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| PT1974747E (pt) * | 1998-08-11 | 2012-09-05 | Biogen Idec Inc | Terapias de combinação para linfomas de células b compreendendo a administração de anticorpo anti-cd20 |
| US6979546B2 (en) * | 1999-11-15 | 2005-12-27 | Universita Di Genova | Triggering receptor involved in natural cytotoxicity mediated by human natural killer cells and antibodies that identify the same |
| HUE033129T2 (en) * | 2003-07-24 | 2017-11-28 | Innate Pharma Sa | Methods and compositions for increasing the efficacy of therapeutic antibodies using compounds that potentiate NK cells |
-
2004
- 2004-07-23 US US10/565,761 patent/US20060240005A1/en not_active Abandoned
- 2004-07-23 EP EP04769123A patent/EP1648508A1/en not_active Withdrawn
- 2004-07-23 JP JP2006520939A patent/JP2006528627A/ja active Pending
- 2004-07-23 WO PCT/IB2004/002637 patent/WO2005009466A1/en not_active Ceased